ESR2 and breast cancer: In contrast to ERα, activation of ERβ generally leads to the inhibition of proliferation, migration, and invasion in HR+ BC,37 and the ERβ-mediated anti-hormonal treatments can be beneficial for triple-negative BC therapy.38